Clinical Trials Logo

Clinical Trial Summary

1. To determine the prevalence of multidrug resistance bacteria in patient with different infections 2. To evaluate patients' predictive risk factors of antimicrobial resistance 3. To assess the association between patients' factors and prevalence of MDR bacteria


Clinical Trial Description

Antimicrobial resistance is one of the most critical public health issue in this century . WHO declared antimicrobial resistance as one of the top ten global health threats that impend the effective management and prevention of evolving infections . Antimicrobial resistance nowadays poses a big challenge because of the emerging of resistance to the antibiotics that previously effective and development of multidrug resistance infections with subsequent increase in morbidity, mortality and financial loss . In spite of WHO health strategies that taken to face multidrug resistance problem, the burden of antimicrobial resistance in Europe is compared with combined burden of influenza and HIVS .while in USA the estimated antibiotics resistance infections is 2.8 millions and the related deaths exceeded 35,000 every year and expected to reach to ten million deaths with collective cost of 100 trillion USD annually in 2050 . Numerous studies reported that self-medications, improper prescription, overuse of antibiotics, deficiency of antibiotics susceptibility test and limited knowledge and attitude of population towards antibiotics are the main factors that lead to antibiotics efficacy being reduced with long hospital stay. Other studies stated that the predictive indicators of MDR tragedy are age, gender, comorbidities, previous hospital stay or antibiotic use . In low and middle income countries like IRAQ there is a difficulty in estimation the scope of antibiotics resistance problem and its evolving over time due to the lack of surveillance, besides alarmingly excessive antibiotics consumption added other challenges and urged us to aim this study . ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05100407
Study type Observational
Source Kufa University
Contact
Status Completed
Phase
Start date March 1, 2022
Completion date May 15, 2022

See also
  Status Clinical Trial Phase
Terminated NCT03309358 - A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis Phase 1
Completed NCT02909946 - Pathway From Functional Disability to Antimicrobial Resistance in Nursing Home Residents N/A
Recruiting NCT04335383 - Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies
Recruiting NCT04181112 - Fecal Transplant for MDRO Decolonization N/A
Completed NCT05048693 - Use of New Antibiotics in Sweden
Completed NCT05897801 - Distinguishing Bacterial and Viral Infections by MeMed BV® Test to Limit Gut Colonization by MDRO
Completed NCT04212130 - Can Environmental Cleanliness be Assessed by BCA (Bicinchoninic Acid) Method N/A
Completed NCT05549427 - Ventilator Associated Pneumonia by Multi-Drug Resistant Organism
Not yet recruiting NCT06370299 - Screening of Multidrug Resistant Bacteria, and the Clinical Implication for the Patient
Recruiting NCT06148480 - Perinatal Transmission of MDR Bacteria
Recruiting NCT04995133 - Colistin Intravenous Administration in Critically Ill Patients Suffering From Hospital Infections Caused by Multi-antibiotic-resistant Germs. Phase 4
Recruiting NCT03921645 - Use of Aaerosol Combined With Intravenous Antibiotics for the Treatment of Multidrug Resistant GNB Pneumonia N/A
Completed NCT06199141 - Multi-drug Resistant Gram-negative Bacteria and Veno-venous Extracorporeal Membrane Oxygenation (ECMO)
Recruiting NCT04759001 - FMT for the Decolonization of Carbapenem-resistant Enterobacteriaceae Phase 1/Phase 2
Not yet recruiting NCT05791396 - FMT to Eradicate Intestinal Colonization by Carbapenem-resistant Enterobacteriaceae Phase 1/Phase 2
Terminated NCT02906774 - Fecal Transplant for MDR Pathogen Decolonization
Recruiting NCT06036628 - Resistant Bacteria in Children in France